BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ), a clinical-stage oncology company focused on RNA therapeutics, announced on Wednesday that it has entered into a securities purchase agreement to raise ...
BOSTON, July 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to more effectively treating ...
10don MSN
DNA transcription is a tightly choreographed event: How RNA polymerase II regulates the dance
Life's instructions are written in DNA, but it is the enzyme RNA polymerase II (Pol II) that reads the script, transcribing ...
Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 ...
RNA clusters (green colored) gradually disassemble within biomolecular condensates (magenta colored), returning the RNA to a soluble state. This occured after an antisense oligonucleotide engineered ...
TransCode Therapeutics RNAZ reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode Therapeutics ( (RNAZ)) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback